Asia-Pacific medical radioisotopes supply TGA

Key Takeaways

• TGA radiopharmaceutical regulation consultation opened 5 June 2026 and closes 31 July 2026.
• Section 19A TECHNELITE (Taiwan) Tc-99m generator approval runs until 30 June 2026 for medicines in short supply.
• Short-supply ARTG generators cited: 72820, 75859, and 130301 (Mo-99/Tc-99m sterile generators).
• Australian Lu-177 trials (e.g., NCT04343885, NCT04786847) show rising therapeutic isotope demand alongside diagnostic Mo-99/Tc-99m.

APAC radioisotope supply signals at a glance

Signal	Detail	Source
Regulatory review	TGA public consultation on radiopharmaceutical regulation (5 Jun–31 Jul 2026)	TGA Citizen Space
Shortage contingency	Section 19A TECHNELITE Tc-99m generator (Taiwan) to 30 June 2026	TGA Section 19A listing
Affected ARTG goods	GENTECH / TECHNELITE Mo-99/Tc-99m generators 72820, 75859, 130301	TGA Section 19A page
Imaging uses named	Brain, thyroid, salivary gland, and blood-pool imaging with Na-pertechnetate	TGA Section 19A indication text
Therapeutic demand	Lu-177 PSMA programmes at Australian centres (NCT04343885; NCT04786847)	ClinicalTrials.gov

What is the TGA consulting on for radiopharmaceuticals?

The TGA’s open consultation on radiopharmaceutical regulation in Australia opened on 5 June 2026 and closes on 31 July 2026. The agency asks for high-level stakeholder feedback on how current regulatory settings operate in practice, including pathways, exemptions, and access mechanisms.

A May 2026 information paper accompanies the consultation. Feedback is intended to inform later targeted engagement—not to rewrite the Therapeutic Goods Act in a single step. Sponsors and nuclear-medicine operators across APAC watching Australian access rules should treat this as an active policy window through end-July 2026.

How do TGA rules treat radiopharmaceutical ARTG entries?

The TGA radiopharmaceuticals guidance for ARTG applications defines radiopharmaceuticals to include ready-for-use products, kits/precursors combined with radionuclides, radionuclide generators, and precursors used for radiolabelling before administration.

Product Information must use SI radioactivity units (becquerels) and radiation dosimetry aligned with ICRP Publication 103 where data exist. Those dossier expectations matter when sponsors seek ARTG inclusion for generators or therapeutic labelled products serving Australian—and often export—supply chains.

Why is a Taiwan TECHNELITE generator under Section 19A?

The TGA Section 19A approval page for TECHNELITE technetium (Tc-99m) generator (Taiwan) lists Global Medical Solutions Australia Pty Limited as approval holder, with approval until 30 June 2026 and status “Current” as published.

The page states the approval addresses medicines in short supply or unavailable: GENTECH Mo-99/Tc-99m generators ARTG 72820 and 75859, and TECHNELITE Mo-99/Tc-99m generator ARTG 130301. Indication text covers preparation of sodium pertechnetate [99mTc] injection for brain, thyroid, salivary gland, and blood-pool imaging. Section 19A is a contingency import/supply tool when ARTG-listed goods are unavailable and public-health criteria are met.

How do Australian Lu-177 trials show therapeutic isotope demand?

ClinicalTrials.gov study NCT04343885 (UpFrontPSMA) is an Australian Phase 2 randomised trial of sequential 177Lu-PSMA-617 then docetaxel versus docetaxel in metastatic hormone-naive prostate cancer. The registry lists 140 patients at 11 Australian centres, with primary completion March 2026, and collaboration including ANSTO among other partners.

ClinicalTrials.gov study NCT04786847 (ProstACT SELECT) is a completed Telix Pharmaceuticals Phase 1 safety, biodistribution, and dosimetry study of 177Lu-DOTA-TLX591 in PSMA-expressing mCRPC at Australian sites. Together these records show APAC clinical demand extending from Mo-99/Tc-99m diagnostics into Lu-177 therapeutics—raising the stakes of resilient isotope logistics and regulator-ready manufacturing.

What does this mean for APAC nuclear medicine planners?

Diagnostic Mo-99/Tc-99m shortages and therapeutic Lu-177 growth pull on different parts of the same regional ecosystem: production, transport half-life constraints, GMP labelling, and dual medicine/radiation licensing. Australia’s concurrent consultation and Section 19A contingency are concrete APAC-visible signals for hospital nuclear medicine departments and radiopharma sponsors.

Related NovaPharmaNews APAC coverage includes TGA Australia drug approval context, Nektar pipeline regulatory context, and drug-discovery technology market analysis.

What remains unproven?

OECD-NEA workshop materials are not allowlisted primary sources for this brief and are not cited as evidence of attendance figures or policy outcomes. The Section 19A page does not quantify national imaging postponements. Trial registries document study design and sites, not commercial Lu-177 supply contracts. Consultation feedback has not yet produced a final TGA rule change.

Frequently Asked Questions

Primary Sources

1. TGA consultation: Radiopharmaceutical regulation in Australia (closes 31 July 2026)
2. TGA Section 19A: TECHNELITE Tc-99m generator (Taiwan)
3. TGA guidance: Radiopharmaceuticals ARTG application information
4. ClinicalTrials.gov: UpFrontPSMA / NCT04343885
5. ClinicalTrials.gov: ProstACT SELECT / NCT04786847